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Abstract
Background: Ovarian cancer is the 5th leading cause of cancer related deaths in women. Five-year survival rates for early
stage disease are greater than 94%, however most women are diagnosed in advanced stage with 5 year survival less than
28%. Improved means for early detection and reliable patient monitoring are needed to increase survival.
Methodology and Principal Findings: Applying mass spectrometry-based proteomics, we sought to elucidate an
unanswered biomarker research question regarding ability to determine tumor burden detectable by an ovarian cancer
biomarker protein emanating directly from the tumor cells. Since aggressive serous epithelial ovarian cancers account for
most mortality, a xenograft model using human SKOV-3 serous ovarian cancer cells was established to model progression to
disseminated carcinomatosis. Using a method for low molecular weight protein enrichment, followed by liquid
chromatography and mass spectrometry analysis, a human-specific peptide sequence of S100A6 was identified in sera
from mice with advanced-stage experimental ovarian carcinoma. S100A6 expression was documented in cancer xenografts
as well as from ovarian cancer patient tissues. Longitudinal study revealed that serum S100A6 concentration is directly
related to tumor burden predictions from an inverse regression calibration analysis of data obtained from a detergent-
supplemented antigen capture immunoassay and whole-animal bioluminescent optical imaging. The result from the animal
model was confirmed in human clinical material as S100A6 was found to be significantly elevated in the sera from women
with advanced stage ovarian cancer compared to those with early stage disease.
Conclusions: S100A6 is expressed in ovarian and other cancer tissues, but has not been documented previously in ovarian
cancer disease sera. S100A6 is found in serum in concentrations that correlate with experimental tumor burden and with
clinical disease stage. The data signify that S100A6 may prove useful in detecting and/or monitoring ovarian cancer, when
used in concert with other biomarkers.
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Ovarian cancer (OVCA) accounts for only 4% of cancer cases
in women, yet it is the fifth leading cause of cancer death and the
most lethal gynecological cancer in this population [1]. In 2008,
there were an estimated 21,650 new cases and 15,520 deaths in the
US [1]. Cisplatin, a platinum-based chemotherapeutic introduced
in 1978, has become an essential part of an OVCA chemotherapy
regimen and has greatly improved the outcome of early stage
OVCA [2]; the 5-year survival rate for stage I patients is greater
than 94% (http//:seer.cancer.gov/csr/1975_2006). Unfortunate-
ly, OVCA is rarely diagnosed at early stage when the disease is
confined and often asymptomatic. Nearly 70% of OVCA cases are
detected at disseminated stages, i.e. stages III and IV, during
which the 5-year survival rate decreases to 30% or less.
An urgent OVCA research priority is the discovery and
validation of biomarkers useful for diagnosing the most deadly
types of OVCA, which often progress rapidly [3]. The only
available FDA-approved non-invasive procedure for ovarian
cancer diagnosis to date is the measurement of serum CA-125
levels. Even though 80% of patients with advanced OVCA have
elevated serum CA-125, there is a high false positive rate
associated with the CA-125 test [4–6]. Physical conditions such
as pregnancy, pelvic inflammatory disease, benign cysts, uterine
fibroids, or infection may also increase serum CA-125 levels [7,8].
Other malignancies including pancreatic, lung, breast, gastric and
colon cancers have also been shown to increase serum CA-125
[4,8].
The emergence of mass spectrometry (MS) proteomics technol-
ogy has brought new opportunities for discovering specific protein
markers for early OVCA detection. Human serum stands as an
attractive specimen for biomarker discovery using MS because
sample acquisition is minimally invasive, and serum is the standard
physiological fluid used for diagnostic purposes. However, the
complexity and wide dynamic range of serum protein concentra-
tion make analysis of a total serum proteome challenging; serum
protein concentrations vary .9 orders of magnitude and 99% of
total serum protein mass is constituted by only approximately 22
protein species [9]. Such challenges associated with serum
proteomics for biomarker discovery will not be easily overcome
[8,10]. Therefore, additional experimental approaches incorpo-
rating MS technology and serum sample processing should be
examined in order to discover clinically relevant OVCA
biomarkers. Indeed, methods such as depletion of abundant
proteins using affinity columns and protein fractionation have
been employed to increase the probability of uncovering tumor-
derived protein species, which are often in low abundance [11].
An approach holding significant potential is analysis of the low
molecular weight serum proteome/peptidome [12]. Low molec-
ular weight (LMW) proteins and peptides often bind to high
molecular weight serum proteins, thereby prolonging half-lives of
the LMW fraction in circulation [13–15]. Thus, serum LMW
proteome represents an attractive reservoir where tumor-derived
low abundant proteins and peptides may be better preserved and
potentially detected.
The development and use of OVCA animal models may serve
as supplemental aids in identifying and confirming predictive
serum biomarkers. The use of animal models has the prospect of
minimizing some of the profound genetic and environmental
variability often encountered in human proteome studies where
unbiased control samples are often difficult to obtain [16]. Such
studies using human cancer xenograft models have been published
previously [17–20]. Transplantation of human cancer in immu-
nodeficient mice is a useful model for the discovery of proteomic
serum or plasma profiles that correlate with tumor burden. These
models have the added benefit of providing means to determine if
the biomarker of interest is derived directly from the cancer cell or
is a product of the host response because one can examine the
presence of tumor cell-derived human specific proteins. Target
biomarkers identified by MS could then be further validated in
such models, thereby increasing the probability of obtaining a
pathologically relevant marker. Consequently, a human OVCA
mouse model was established in an attempt to discern ovarian
cancer-derived proteins in serum using MS-based discovery. This
approach revealed the presence of S100A6, in addition to other
human proteins, in sera from mice with OVCA. Expression of
S100A6 was further examined in human cancer cell lines and
tissue derived from OVCA patients. In addition, a system was
sought to correlate quantity of serum S100A6 and tumor burden
in the model. The latter aim endeavors to begin addressing
important unanswered questions regarding a tumor size necessary
to permit de novo detection of protein signatures of the mass in the
blood. Lastly, we sought to validate the expression profile of
S100A6 in human sera using a well-controlled clinical study set of
women with early and advanced stage ovarian cancers.
Results
A general experimental approach for discovering LMW serum
proteins with possible relevance for human OVCA in a mouse
model using MS is depicted in Figure 1. Following intraperitoneal
(i.p.) injection of mice with human serous SKOV-3 OVCA cells or
saline control, blood was sampled at various time points while
early and progressive carcinomatosis was being modeled. The
LMW serum proteome was analyzed to identify proteins specific
to, or more abundant in, cancer-bearing mice. The presence of
tumor-derived S100A6 protein in serum was further studied as a
candidate biomarker using antibody-based analyses. Tumor
burden was correlated with the presence or level of serum protein
S100A6 in the model, which thereby could be considered as a
putative biomarker. The groundwork for further validating the
clinical relevance of these findings for OVCA patients was laid by
detecting more abundant S100A6 in sera from women with
advanced stage disease, compared to early stage disease.
Discovery of OVCA Associated Serum Proteins
The experimental disease progressed from neoplastic cellular
seeding of the peritoneum during engraftment to disseminated
carcinomatosis, mimicking the progression from regional to distant
advanced stage OVCA in women. All SKOV-3-inoculated mice
exhibited multiple, variably-sized infiltrative tan, solid tumor
nodules distributed throughout the peritoneum by 4 weeks post
inoculation (p.i.). This was accompanied by neoplastic effusions in
abdominal cavities of most SKOV-3-inoculated mice. Histologi-
cally, mesenteric masses were composed of a morphologically
variable population of neoplastic ovarian epithelial cells. These
cells occurred as expansile, papillary growths with trabeculae 2–3
cells thick, or as solid densely cellular masses supported by limited
fibrous tissue (Figure 2A and B). All saline-inoculated control mice
remained free of disease.
Index sera harvested from mice with late-stage carcinomatosis
at 4 weeks following inoculation of 1610
6 SKOV-3 human
OVCA cells were analyzed by MS and compared to control
mouse sera (first of 3 study animal cohorts). The data were
scrutinized to determine peptides/proteins with greater abun-
dances in cancer vs. control samples (spectral count analysis).
Overall the analyses yielded identification of about 400 peptides
corresponding to approximately 300 proteins (combined human
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high likelihood of differential abundance, the results of the spectral
count analysis of the human protein database search were filtered
using Scaffold software to yield proteins with a minimum of 10
MS/MS spectra assigned (total of all replicate analyses) and a
statistically significant difference in the number of assigned spectra
(cancer.control) as measured by a t-test (p-value,0.05), or a
minimum of a 100% difference in the spectral counts ((cancer
counts - control counts)/(average cancer and control
counts)6100%). These results are shown in Table 1.
Following identification of these candidate differentially abun-
dant (cancer . control) human proteins, human peptide sequences
identified by MS/MS spectra were then searched against a mouse
database to examine if the peptide sequence was homologous
between human and mouse and to verify the appropriateness of
the sequence call (or if there was ambiguity in amino acid
designation). Proteins were classified by having (1) human-specific
peptides only, (2) peptides homologous to both human and mouse,
and (3) both 1 and 2 (Table 1). Proteins identified by human-
specific peptides are of potentially greater value since they most
likely originated from the xenografted human cancer cells.
S100A6 was selected for further study. In addition to meeting
criteria for significance established for differentiating cancer
associated serum proteins from control specimens (Table 1),
S100A6 was regarded as a candidate for additional validation
because of its increased expression in a variety of human cancers
and its relatively small size (10.5 kDa). In the latter respect,
S100A6 was attractive for its potential to be an intact protein
yielded by the LMW separation strategy used to enrich for
proteins with molecular weight less than ,25 kDa. As shown in
Table 1, three S100A6 peptides were identified; two sequences
common to the human and mouse versions of this protein (red and
blue fonts), and one peptide unique to the human version (green
font) (Figure 3A). The MS/MS spectrum used to identify the
unique human peptide, LMEDLDR, is shown in Figure 3B. The
corresponding mouse sequence has an aspartic acid at the third
residue position, instead of the glutamic acid in the human
sequence. The presence of this human-specific peptide was
subsequently confirmed in a second MS/MS analysis conducted
on serum samples collected from the tumor-bearing mice in the
third cohort of animals (see Materials and Methods).
Expression of S100A6 in OVCA
An anti-S100A6 immunoblot was carried out to confirm the
presence of intact S100A6 in mouse sera used in the MS analyses.
Using a custom anti-human S100A6 antibody, C1, a 10.5 kDa
band corresponding to the molecular weight of S100A6 was
detected in pooled sera collected 4 weeks p.i. from tumor-bearing
mice used for initial MS analyses (Figure 4A). S100A6 was not
detected in sera from matched-study saline-control mice. The C1
anti-S100A6 immunoblot was also performed on additional series
of sera sampled from individual SKOV-3 cell-injected animals
with experimental end stage disease, as well as sera from naı ¨ve
control animals; the S100A6 10.5 kDa band was only observed in
sera from animals with tumors, not in control mouse sera (data not
shown). Evidence for S100A6 protein expression in OVCA
xenografts and mouse abdominal organs was examined using
immunohistochemistry (IHC). S100A6 immunolabeling was
observed in tumor tissue but not in surrounding mesentery or
abdominal organs (intestines, liver, kidney, urinary bladder,
spleen, pancreas, uterus, and ovary) (Figure 4B and C).
The potential clinical relevance of finding S100A6 in the sera of
mice with SKOV-3 xenografts was further investigated by
examining the expression of S100A6 in other OVCA human
Figure 1. Experimental strategy to use MS discovery proteo-
mics in low molecular weight (LMW) serum fraction from a
mouse model of human ovarian cancer. To determine whether
cancer-derived proteins have candidate biomarker potential, (A) a
bioluminescent xenograft model, (B) ECLISA, (C) Western blot, and (D)
OVCA tissue array immunohistochemistry (IHC) are utilized. This was
followed up for S100A6 by analysis of human patient sera.
doi:10.1371/journal.pone.0007670.g001
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and matched normal ovary lysates from 2 patients, S100A6 was
elevated in carcinoma tissue compared to its matched non-
neoplastic ovarian tissues (Figure 5A and B). Human OVCA-
derived cell lines expressed various levels of S100A6 (Figure 5C
and D). All OVCA cells tested, except OVCAR-4 and the cell line
derived from clear cell ovarian carcinoma (ACI-89-2), expressed
S100A6 above background level (normal ovary).
To further delineate differential S100A6 expression in human
OVCA patient tissues, examination of malignant, borderline,
benign, and noncancerous ovarian tissues was performed using
IHC. Tissue sections lacking S100A6 immunoreactivity, similar to
observations in the IHC negative reaction control, were
considered negative. Immunoreactivity clearly above negative
control was assigned as positive. Specimens with few numbers of
weakly positive cells were considered equivocal. Among 140
malignant OVCA specimens, 116 (83%) were positive for S100A6
immunolabeling (Table 2). High S100A6 positive incidence (over
80%) was observed in all malignant types of OVCA with the
exception of clear cell carcinoma, of which only 2 out of 4
specimens were S100A6 positive. Nearly 85% of benign adenomas
showed positive S100A6 reactivity as well; the labeling intensity
was comparable with that of malignant OVCA. No apparent
relationship between labeling intensity and cancer stage or grade
Figure 2. Human OVCA cell xenograft in mouse peritoneal cavity. (A) Representative OVCA exhibits predominantly solid tumor growth, with
evidence of papillary projections and occasional minute cysts (bar=25 mm). Inset, higher resolution photomicrograph depicting cuboidal to
polygonal pleomorphic microcystic epithelium with anisokaryosis and atypical mitoses of ovarian cancer cell nuclei (bar=50 mm). (B) OVCA tumor
nodule implant on uterine infundibulo-ovarian ligament (arrowhead) adjacent to the ovary (arrow) (bar=25 mm). Tumor implants occurred
throughout the peritoneal cavity, peri-ovarian connective tissues, and invaded surrounding tissues such as intestines, liver and diaphragm.
Hematoxylin and eosin (H&E) stained, paraffin-embedded tissue sections.
doi:10.1371/journal.pone.0007670.g002
Table 1. Differentially abundant proteins in serum from OVCA and control (C) mice selected based upon spectral counting.
Protein Accession MW t-test Spectra Unique Human Common Human/Mouse
no. (kDa) p-value (OVCA, C) Peptide Sequences Peptide Sequences
Fructose-bisphosphate aldolase C P09972 39 2.0E-03 30, 0 GVVPLAGTDGETTTQGLDGLSER
Keratin, type II cytoskeletal 1 P04264 66 2.0E-02 16, 0 YEELQITAGR
Calcyclin (S100A6) P06703 10 1.4E-04 29, 0 LMEDLDR ELTIGSK; LQDAEIAR
L-lactate dehydrogenase A chain P00338 37 4.0E-04 28, 8 * DYNVTANSK; VTLTSEEAR SADTLWGIQK
Fructose-bisphosphate aldolase A P04075 39 2.0E-03 35, 0 AAQEEYVKR ALQASALK
GILAADESTGAIAK
Triosephosphate isomerase P60174 27 9.0E-04 13, 0 VTNGAFTGEISPGMIK
Actin, cytoplasmic 1 (Beta-actin) P60709 42 1.5E-02 18, 0 VAPEEHPVLLTEAPLNPK
Fibrinogen beta chain precursor P02675 56 3.0E-01 12, 0 EDGGGWWYNR
Fibronectin precursor P02751 63 6.0E-01 6, 1 VGDTYERPK
Coagulation factor X precursor P00742 55 8.0E-01 9, 1 MLEVPYVDR
Apolipoprotein E precursor P02649 36 5.0E-01 14, 2 LGPLVEQGR
Proteasome subunit alpha type 6 P60900 27 6.0E-02 18, 3 3 common sequences
Proteasome subunit alpha type 3 P25788 28 8.0E-02 17, 4 2 common sequences
Actin, aortic smooth muscle P62736 42 2.0E-05 35, 8 3 common sequences
*One peptide sequence identified in controls is unconfirmed and differs from those identified in cancers.
doi:10.1371/journal.pone.0007670.t001
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neoplastic tissue adjacent to tumors exhibited limited or no
S100A6 labeling. These results, demonstrating S100A6 expression
in a variety of patient-derived epithelial ovarian cancer cell lines
and tissues, establish that expression of S100A6 in OVCA is fairly
common. In this context, finding human-specific S100A6 peptide
sequence in serum from human OVCA-bearing mice indicates
that S100A6 may have benefit as a candidate protein for
monitoring OVCA. Furthermore, positive expression of S100A6
in benign and malignant OVCA, in contrast to its virtual absence
on the surface of normal ovary, suggests S100A6 may be suitable
as a marker in diagnostic imaging to help locate and corroborate
ovarian proliferative changes.
Serum S100A6 Level Correlates With OVCA Tumor
Burden
To determine whether the quantity of S100A6 in serum could
be used as a correlate for estimating tumor burden, in vivo
bioluminescent imaging and a modified ELISA assay (ECLISA)
were applied. First, to provide estimates of tumor burden in cell
numbers, 35 animals were injected with varying numbers of
luciferase expressing SKOV-3 cells (SKOV-3-Luc) and in vivo
bioluminescent photon signals were quantified (second cohort,
Human Ovarian Cancer Animal Model, Materials and Methods).
Regression analysis was performed on (log10) photon output vs.
(log10) numbers of inoculated cells to produce a standard
calibration curve (Figure 6A). An inverse prediction equation
(see Materials and Methods) was derived from the regression
analysis to obtain estimates of cell numbers, i.e., predicted tumor
burden from the photon flux output of live animals.
To determine whether serum S100A6 levels escalated as tumor
burden increased with time on study, mice were injected with
SKOV-3-Luc or saline (third cohort, Human Ovarian Cancer
Animal Model, Materials and Methods). On days 9, 15, 21 and 28
p.i., all SKOV-3-Luc-inoculated mice were optically imaged to
obtain the photon output from growing cancers. Photon flux data
were then converted to estimates of in vivo tumor cell burden. Ten
animals each from tumor-bearing and control groups were bled
and removed from study at each time point; serum S100A6 level
Figure 3. S100A6 protein sequence. (A) Aligned human and mouse S100A6 sequences depicting 3 amino acid differences between the two
species (vertical lines). Three peptides were detected by LC-LTQ MS/MS from tumor-bearing mouse sera; sequences are shown in color font. Peptides
in red and blue font are homologous for human and mouse, while the peptide sequence in green font is unique to human S100A6, due to one amino
acid difference. (B) MS/MS spectrum of the human-specific S100A6 peptide, LMEDLDR. This sequence was not detected in saline-inoculated control
mice sera.
doi:10.1371/journal.pone.0007670.g003
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serum S100A6 concentration from tumor-bearing mice and saline-
injected controls revealed that, as early as 9 days p.i., there was
significantly greater serum S100A6 concentration in the tumor-
bearing mice, well before any identifiable tumor masses were
present; the significant differential serum S100A6 level persisted
through day 15 to day 21 p.i. (Figure 6B). Most day 28 p.i. serum
specimens were used for MS/MS analysis, and the numbers of
remaining serum samples were insufficient for this statistical
comparison.
The correlation between tumor burden and the serum
S100A6 level in specimens from these same SKOV-3-Luc-
injected mice was sought next. When tumor burden (cell
number) was plotted against serum S100A6 protein concentra-
tion in these animals, results indicated a highly significant
correlation (r=0.79, p,0.0001); serum S100A6 concentration
was greater as the tumor burden increased over time for animals
given SKOV-3-Luc (Figure 6C). The amount of S100A6 in
saline-injected control mice remained near a basal level at all
study time points, typically approximating the lower limit of
S100A6 ECLISA detection (Figure 6B, SC). Escalating concen-
trations of S100A6 were also observed in sera collected serially at
1, 2, and 4 weeks p.i. from individual mice within the initial
cohort of 20 mice given the parental SKOV-3 cell line (data not
shown).
Serum S100A6 Levels in Human OVCA Study Sets Are
Linked To Disease Stage
In order to determine if there was an association between
elevated S100A6 protein and tumor burden in women with
OVCA, we performed a pilot experiment using a well-
controlled human clinical study set of 66 diagnostic serum
samples that was available to us through the USA-ITALY
Oncoproteomics Program. Sera had been obtained prior to
therapy from women with early stage (I-IIb) and borderline
OVCA (n=23), and from women with advanced stage (IIc-IV)
disease (n=43). Immunoblots, with the C1 anti-S100A6, were
carried out on a reverse phase protein microarray (RPMA) slide.
Using this technique, levels of S100A6 were found to be
statistically elevated in the sera of women with advanced stage
disease compared to those with early stage tumors (p=0.031),
demonstrating an association between clinical features of
greater tumor burden and increased levels of S100A6 in OVCA
patients (Figure 7).
Figure 4. S100A6 protein expression in mouse serum and
OVCA tissue. (A) Immunoblot analysis for the presence of S100A6 in
pooled raw sera from cancer-bearing mice (1) and saline control mice
(2). The sera were used in LMW protein fraction preparation for MS
analysis in biomarker discovery. (B) OVCA xenografts express S100A6 as
analyzed by IHC. Tumor xenograft implant on intestinal mesentery
reveals S100A6 protein limited to tumor, with lack of immunolabeling in
adjacent intestines and mesentery. (C) Serial section from tissue shown
in B, used for IHC reaction control, reveals lack of immunoreactivity
when primary S100A6 antibody is omitted from IHC. Immunoperox-
idase, hematoxylin counterstain (Bars=50 mm).
doi:10.1371/journal.pone.0007670.g004
Figure 5. S100A6 expression in human OVCA cell lines and tissues by Western blot analysis. (A and B) Paired lysates of OVCA (cancer)
and adjacent normal ovary tissue (normal) from 2 OVCA patients were blotted for S100A6 expression. SKOV-3 cell lysate was used for comparison. (C
and D) S100A6 expression in OVCA cell lines from NCI60 (SKOV-3, OVCAR-3, 4 and 5) as well as cell lines derived from OVCA patients (see also
Materials and Methods).
doi:10.1371/journal.pone.0007670.g005
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S100A6 was identified in the sera of mice with human OVCA
using an MS/MS-based bottom-up proteomics strategy in an
attempt to discover candidate biomarkers derived from tumor
mass. The human tumor-origin of the S100A6 was established for
the model, and the serum concentration of S100A6 correlated
with the amount of experimental cancer present. Further clinical
relevance was demonstrated through discovery of the potential for
serum S100A6 to correlate with tumor burden using human
clinical study sets.
During the discovery phase, a serum separation method to isolate
the LMW proteome was employed to enrich proteins/peptides
circulating in relatively low abundance, addressing the complexity
of the whole serum proteome. The human SKOV-3 cell xenograft
mouse model provided the opportunity to evaluate species
differences in the effort to classify cancer-associated proteome as
either tumor-derived (human) vs. host response (mouse). More in
depth clinical validation studies are warranted to examine the
potential for serum S100A6 to serve as a candidate biomarker for
the evaluation of women with OVCA, particularly for monitoring
recurrence. This premise is supported by the following evidence: (1)
presence of a human-specific peptide sequence of S100A6 in sera,
(2) detection of S100A6 protein expression in experimental tumors
but not in surrounding non-neoplastic mouse tissues, (3) a positive
and direct correlation between S100A6 serum concentration and
tumor burden in the xenograft model, (4) demonstration of elevated
S100A6expressionintissuesandcelllinesfromOVCApatients,but
rarely in normal ovary, in this and other studies [21,22], and finally,
(5) significant elevation of the analyte in the sera of women with
advanced stage OVCA vs. women with early stage disease. Limiting
initial screening in mice to the SKOV-3 cell line in this case
therefore did not preclude identifying a possible clinical surrogate
biomarker for further validation. Additional human OVCA tissue-
associated proteins were also reported in serum using this approach,
and these can be tested further for candidate biomarker potential
using the strategy applied here.
S100A6 was pursued for initial validation as a candidate serum
biomarker due to its association with cancer progression [22,23].
S100A6 is a small calcium binding protein that belongs to the S100
protein family. The approximately 25 members of the S100 family
are characterized by 2 EF-hand structures and likely have calcium
sensor function [24]. S100 proteins have been implicated in a wide
range of physiological and pathological processes including cell
proliferation, differentiation and intracellular signaling, although
their exact functions remain to be defined further [24–27]. With
respect to S100A6, its expression is normally found in fibroblasts
and epithelial cells [28], and elevated S100A6 has been reported in
a number of human cancer types including carcinomas of colon,
pancreas, breast, ovary, lung and thyroid gland [29–35] .
There are conflicting reports about the role S100A6 plays in
cancer. Vimalachandran et. al. [29] studied the expression pattern
of S100A6 as it pertained to clinical outcome in pancreatic cancer
and S100A6 expression was a negative prognostic factor. High,
specifically nuclear, expression of S100A6 was associated with a
poor prognosis. In addition, a stepwise increase of S100A6 during
pancreatic carcinogenesis has been reported [36]. By contrast,
elevated levels of S100A6 decreased the mobility of osteosarcoma
cells and were associated with decreased clinically evident
metastases [37]. Similarly, increased S100A6 expression was
associated with a survival benefit for non-small cell lung cancers
[35]; S100A6 was demonstrated in 2 lung cancer patients’ sera,
and in the pleural effusion of one. In the present study, we have
extended the value of S100A6 to include it as an OVCA serum
biomarker by demonstrating positive expression in human OVCA
using immunohistochemistry, as well as an association between
S100A6 serum level and tumor burden in both mice and human
patients. The fact that S100A6 is elaborated by a number of
human cancers, suggests that its use as a sole biomarker may
encounter potential false positive incidences, akin to CA-125.
Therefore, incorporating S100A6 into a panel of cancer
biomarkers represents a logical approach to be pursued.
The low incidence of OVCA makes establishing and validating
clinical biomarkers using human specimens difficult. Only 1 in
Table 2. S100A6 immunohistochemical findings in epithelial OVCA and ovary tissues.
Ovary Pathology Diagnosis No. of Patient Cases Positive (%) Negative (%) Equivocal (%) *
Malignant
Serous Adenocarcinoma 87 70 (80%) 14 (16%) 3 (4%)
Mucinous Adenocarcinoma 13 13 (100%) 0 (0%) 0 (0%)
Endometrioid Adenocarcinoma 20 16 (80%) 2 (10%) 2 (10%)
Transitional Cell Carcinoma 6 5 (83%) 1 (17%) 0 (0%)
Clear Cell Carcinoma 4 2 (50%) 2 (50%) 0 (0%)
Metastatic Serous Adenocarcinoma 10 10 (100%) 0 (0%) 0 (0%)
Total 140 116 (83%) 19 (13.5%) 5 (3.5%)
Borderline
Borderline Serous/Mucinous Cystadenoma 5 4 (80%) 1 (20%) 0 (0%)
Benign
Benign - Adenomas 13 11 (85%) 1 (7.5%) 1 (7.5%)
Normal
Non-Neoplastic Tissue Adjacent to Tumor 16 2 (13%) { 13 (81%) 1 (6%)
Morphologically Normal Ovary 13 0 (0%) 12 (92%) 1 (8%)
Total 29 2 (7%) 25 (86%) 2 (7%)
*Equivocal = weak labeling or rare positive cells. { Reactive hyperplastic ovarian surface epithelium.
doi:10.1371/journal.pone.0007670.t002
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OVCA annually [38,39]. Because of this low incidence, popula-
tion screening requires a large number of patients and therefore is
very expensive for OVCA biomarker discovery and validation. For
this reason the use of an animal model can be a cost efficient
means to provide preclinical data to justify a large clinical
validation study. Utilizing OVCA animal models for this purpose
necessitates fidelity to both experimental aims and recapitulating
cardinal features of human disease biology. The host of gene-
targeted mutant mice developed for functional genomic studies has
overshadowed application of human xenograft cancer models in
some arenas recently [40]. Certain limitations of using mouse
xenograft models for developing candidate biomarkers, such as
engraftment of cultured cells, use of an immunocompromised host,
and absence of cancer initiation from the ovary itself, must be
acknowledged to permit a more precise focus on how data may be
best applied to clinical disease. Nevertheless, the OVCA disease
features produced in this study, recapitulating early neoplastic cell
seeding of peritoneum and progression to advanced carcinoma-
tosis, represents typical clinical case management situations.
Indeed, over the last decade more than 80% of patients presented
with metastatic disease within the pelvis or abdomen at the time of
diagnosis [41]. Features of the experimental pathology faithfully
recapitulate more advance stage disease biology (stages III and
IV). Consequently, discovery of S100A6 as a surrogate for tumor
burden in the model appears to have been predictive of the
findings in women with advanced stage OVCA. Such a
relationship further suggests that the model may be suitable for
mimicking re-exacerbation of disease post surgical debulking, and
for use in developing markers for patient monitoring. Concerns
about limitations on discovery using xenograft models must be
Figure 6. Detection of S100A6 in serum over time from mice
with OVCA, in association with estimated peritoneal cavity
tumor burden. (A) Photon flux measurements obtained from mice
harboring defined numbers of bioluminescent SKOV-3-Luc cells within
the peritoneal cavity. Regression analysis was performed on (log10)
photon output vs. (log10) numbers of inoculated cells to produce a
standard calibration curve using an inverse prediction equation (see
Materials and Methods). This was used to predict tumor burden from
photon flux measurements (see also figure 6C). (B) Comparisons of
serum S100A6 in tumor-bearing (T, closed circles) and saline-inoculated
control mice (SC, open circles). Serum S100A6 concentrations, tested as
individual specimens from multiple mice by ECLISA (plotted as
individual values with horizontal line at median value), were
significantly different between T vs. SC at each of three times tested
post inoculation, 9 days (p=0.015), 15 days (p=0.036), and 21 days
(p=0.0031) (Wilcoxon Rank Sum test). (C) Correlation between estimate
of tumor burden in OVCA carcinomatosis and concentration of serum
S100A6, as measured by ECLISA from tumor-bearing mice (r=0.79,
p,0.0001).
doi:10.1371/journal.pone.0007670.g006
Figure 7. Reverse phase protein micorarray data obtained from
the analysis of diagnostic sera from women with OVCA.
Scatterplot displays relative intensity of serum S100A6 values for
women with early stage (open circles, n=23) and advanced stage
(closed circles, n=43) OVCA. The early stage disease group includes 2
tumors diagnosed as borderline OVCA. The means of the relative
intensity values of the analyte concentrations shown (horizontal lines)
are significantly different for the two groups (p=0.031, two-sample t-
test), and depict relatively greater mean S100A6 concentration in sera
of advanced stage patients.
doi:10.1371/journal.pone.0007670.g007
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animal model, as well as the relevant clinical pathophysiology
being investigated [40,42].
In the present study, the human disease model permitted
elucidation of the kinetics of S100A6 during OVCA disease
progression prior to its clinical application. This was accomplished
by developing and applying a novel antigen capture immunoassay,
ECLISA, permitting in-solution analysis with a lower limit of
detection in the range of 10–50 ng/mL of serum. By our analyses,
the concentration of S100A6 in the range of approximately
100 ng/mL was considered to represent approximately 2–5
million OVCA cells in the peritoneal cavities of mice. Five million
pelleted SKOV-3 cells have a mass of ,20 mg; thus the assay
would presumably enable detection of a minimal tumor cell load
of about a 0.08% or less tumor to body weight ratio. It is worth
noting that LMW proteins/peptides often associate with high
molecular weight proteins in circulation [12–15], and therefore the
antigenic epitopes of bound LMW proteins and peptides may not
be readily available for antibody recognition. This issue was taken
into consideration while developing the S100A6 ECLISA. It is
important to emphasize that evidence for high molecular weight
protein binding in the case of S100A6 was not substantiated
conclusively, however antibody detection of S100A6 in solution
did require addition of detergent (0.16% SDS) in raw serum in
order to render the analyte available for antibody binding and to
obtain optimal ECLISA signals. The RPMA employed used the
same C1 anti-S100A6 that was used in the ECLISA, providing
independent validation of S100A6 detection in serum. Other
investigations comparing findings obtained from analyses of sera
by both RPMA and ELISA-based assays indicate that they yield
strongly correlative results [43,44].
In conclusion, this study demonstrates the presence of S100A6
in OVCA cancer sera for the first time and further documents the
potential use of S100A6 as an OVCA biomarker. Using a human
xenograft model simulating disseminated growth of OVCA, serum
S100A6 level, derived from the tumor tissue, directly correlated
with increasing tumor burden and disease progression. In keeping
with the observations that S100A6 correlates with tumor burden
in the mouse model, and supporting further exploration of this
biomarker for recurrence monitoring, we found that women with
advanced stage OVCA had relatively increased levels of S100A6
in their blood compared to women with early stage disease.
Additional studies exploring more deeply the true positive
predictive value of S100A6 either alone, or in combination with
CA-125 and other protein candidates resulting from this study, in
a monitoring setting, are required and are ongoing. Aims will
include a focus on creating what will likely be panels of tumor-
derived serum proteins for use as markers in various OVCA
disease constellations.
Materials and Methods
Human Ovarian Cancer Cells
SKOV-3 ovarian cancer cell line was purchased from American
Type Culture Collection (ATCC) (Manassas, VA). SKOV-3 cells
were cultured in McCoy’s 5A medium (ATCC, Manassas, VA)
supplemented with 10% fetal bovine serum and 100 units/mL
penicillin G sodium, 100 mg/mL streptomycin sulfate, and 292 mg/
mL L-glutamine (Invitrogen Life Technologies, Carlsbad, CA).
Luciferase-expressing cells were generated by infecting SKOV-3
cells with pCLNCX-luciferase retrovirus (SKOV-3-Luc) (a gift
from Dr. Steven Libutti, NCI, Bethesda, MD). Human OVCA cell
lines tested in vitro included OVCAR-3, 4, and 5, from NCI-60 cell
lines (http://dtp.nci.nih.gov/docs/misc/common_files/cell_list.
html), and a series of 7 OVCA cell lines derived by Dr. Risinger
at the Anderson Cancer Institute, Savannah, GA (JIR, unpublished
data). Cells were cultured in DMEM/F12 medium (Invitrogen Life
Technologies, Carlsbad, CA) with the same supplements described
above.
Human Ovarian Cancer Animal Model
Five to seven week-old nude mice (Ncr nu/nu) were obtained
from NCI (Frederick, MD), maintained in accredited animal
facilities and used as stipulated by the U.S. Public Health Service
Policy on Humane Care and Use of Laboratory Animals, in
accordance with institutional reviews (http://oacu.od.nih.gov).
Three cohorts of animals were used in this study. The initial
cohort was comprised of 40 mice that were individually identified,
bled, and given intraperitoneal (i.p.) injection of 1610
6 SKOV-3
or equal volume of sterile saline (APP Pharmaceuticals, Schaum-
burg, IL). Serial blood samples were collected from retro-orbital
sinuses at 1, 2 and 4 weeks p.i. Additional blood samples collected
at study end by cardiac puncture at 4 weeks p.i. were pooled from
both 6 principal and control mice and used in MS analysis for
serum proteomics comparing cancer vs. non-cancer control. Sera
were separated using Microtainer tubes (BS, Franklin Lakes, NJ),
and stored at 280uC until analyzed.
A second cohort of mice was injected with SKOV-3-Luc cells in
order to provide estimates of the number of cells in OVCA tumor
burdens by determining the functional relationship between
bioluminescent signal output and cell numbers. Animals were
injected i.p., as in the previous experiment, using escalating
numbers (5610
5,5 610
6,o r5 610
7) of SKOV-3-Luc cells, 10–15
mice per cell quantity. Two hours after cell inoculation, animals
received i.p. injection of 3 mg luciferin (Thermo-Fisher Scientific,
Rockford, IL) and were imaged using Xenogen IVIS 100 optical
imager according the manufacturer’s guide (Caliper Life Sciences,
Hopkinton, MA). A standard calibration curve of known cell
numbers inoculated vs. photon flux measurements was developed
such that cell numbers, along with their confidence intervals, could
be predicted by inverse regression calibration (see Serum S100A6
Quantification and Data Analysis below).
A third cohort of mice was inoculated with SKOV-3-Luc cells
to provide a timed longitudinal study to examine the kinetics of
serum S100A6 protein, identified by MS analysis of sera from the
first cohort of mice, in its relationship to OVCA tumor burden. A
cohort of 80 animals received 1610
6 SKOV-3-Luc cells (40 mice,
tumor group) or saline (40 mice, control group) on day 0. On days
9, 15, 21 and 28 p.i., all live animals inoculated with cancer cells
were optically imaged to obtain the bioluminescent signals from
engrafted SKOV-3-Luc (Caliper Life Sciences, Hopkinton, MA).
Ten mice in each group (cancer bearing and saline vehicle-
inoculated control groups) were bled by cardiac puncture at each
time point and removed from study. Sera from most of the mice
with late-stage disease collected at 28 day p.i. were pooled for use
in second MS analysis, intended to confirm the initial S100A6
results. Tumors (or mesenteric tissue from early time point and
control mice) were excised at necropsy, immersed in formalin
fixative and subsequently paraffin embedded routinely for
histological examination and IHC.
Mass Spectrometry
LMW serum proteins were prepared and analyzed as described
[45]. In brief, pooled serum samples were prepared from tumor
and control groups by combining equal volumes of serum from
each mouse within the same group followed by thorough mixing.
One hundred microliters of the pooled serum samples were mixed
with 2x SDS-PAGE loading buffer (Invitrogen Life Technologies,
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electrophoresis apparatus, Prep Cell (BioRad Laboratories, CA),
packed with 10% acrylamide gel. Continuous flow denaturing
electrophoresis was accomplished under a constant voltage of
250V. Immediately after the bromophenol blue dye front migrated
out of the gel, LMW peptides and proteins were eluted in Tris-
Glycine running buffer (0.3% Tris, pH 7.4, 1.44% glycine and
0.1% SDS) at a flow rate of 500 mL/minute for 5 minutes per
fraction. Ten microliters of each fraction were loaded onto an
SDS-PAGE gel to examine the molecular weight range of protein/
peptide components in each fraction collected. Fractions contain-
ing proteins/peptides with molecular weights less than ,25 kDa
were combined and concentrated using a Centricon filter
(Millipore, Billerica, MA) to a final volume of 300 mL. SDS was
removed from the LMW protein samples by tricholoroacetic acid
(TCA) precipitation, in which the concentrated proteins/peptides
were incubated with an equal volume of 10% TCA (w/v) on ice
for 1 hour and the mixture then was centrifuged at 15,000x g for
30 minutes at 4uC. The pellet containing the precipitated
proteins/peptides was washed in cold acetone and dissolved in 8
M urea.
T h eS D S - f r e eL M Wf r a c t i o n sw e r ea n a l y z e du s i n ga
traditional bottom-up MS proteomics method. The LMW
peptides/proteins first were reduced and alkylated by reaction
with 20 mM dithiothreitol followed by 100 mM iodoacetamide.
The samples then were digested with trypsin (Promega, Madison,
WI) at 37uC overnight in 50 mM ammonium bicarbonate in the
presence of 1 M urea, and the resulting tryptic peptides were
desalted using a mC18 Zip-Tip (Millipore, Billerica, MA). The
peptide samples were analyzed by liquid chromatography (LC)-
ESI (electrospray ionization)-MS/MS using an LTQ linear ion
trap mass spectrometer (Thermo Scientific, San Jose, CA). An
aliquot of each sample was loaded onto a home-made reverse-
phase C18 column that consisted of a 10 cm long, 100 mmi n n e r
diameter piece of fused silica packed with 5 mm2 0 0A ˚ pore size
C18 resin (Michrom Bioresources, Auburn, CA) with an
integrated laser-pulled tip. After loading the sample, the column
was washed for 5 minutes with LC solvent A (0.1% formic acid)
and then the peptides were eluted with a flow rate of 250 nL/
minute using a linear gradient from 0% solvent B (0.1% formic
acid, 80% acetonitrile) at 5 minutes to 50% B in 30 minutes and
then to 100% B in an additional 5 minutes. The LTQ was
operated in a data-dependent mode in which each full MS scan
w a sf o l l o w e db yf i v eM S / M Ss c a n sw h e r e b yt h ef i v em o r e
abundant ions in the MS scan were selected dynamically,
fragmented by collision-induced dissociation and the fragment
ions detected. Multiple replicate analyses of serum pool aliquots
were performed.
T h em a s ss p e c t r a ld a t aw e r es e a r c h e da g a i n s tt h eS w i s s -
Prot databases of human and mouse proteins using the
SEQUEST algorithm as part of theB i o w o r k ss o f t w a r e( T h e r m o
Scientific, San Jose, CA) with a full tryptic cleavage requirement
and a static cysteine alkylation modification. High confidence
peptide identifications were obtained by filtering the search
results based on the following criteria: minimum cross-
correlation score of 1.8 (+1 ion), 2.2 (+2) and 3.5 (+3); minimum
delta Cn of 0.1 and maximum probability of a random match of
0.01. These match criteria yielded false discovery rates of 1–5%.
In addition, all matches corresponding to peptides that were
deemed to potentially be differentially abundant in cancer vs.
control samples were evaluated by manual inspection of the
data. Comparative analysis based on spectral counting was
accomplished using Scaffold (Proteome Software, Inc., Portland,
OR).
Cell Lysate Preparation and Western Blot Analysis
Paired OVCA and matched normal ovary tissue protein lysates,
from two patients, were obtained from Abcam (Cambridge, MA).
Cultured cells were lysed in RIPA buffer (Cell Signaling
Technology, Danvers, MA) for 20 minutes at 4uC. Cell lysates
were centrifuged at 13,0006 g for 5 minutes to remove cellular
debris. One microliter of mouse serum or 2.5 mg of clarified cell
lysates were separated on 4–20% Tris-Glycine gradient gels
(Invitrogen Life Technologies, Carlsbad, CA) and transferred to
Immun-Blot PVDF membranes (Bio-Rad Laboratories, Hercules,
CA). The membranes were blocked in 3% bovine serum albumin,
blotted with primary antibodies followed by peroxidase-conjugat-
ed secondary antibodies (Jackson ImmunoResearch Laboratories,
Inc. West Grove, PA). The antibody reactivity was detected using
electrochemiluminescent (ECL) Western Blotting Substrate
(Thermo Fisher Scientific, Rockford, IL). Rabbit anti-human
S100A6, C1 (see S100A6 Quantification section) and mouse anti-
human b-actin (Sigma Aldrich, St. Louis, MO) were used as
primary antibodies at a working concentration of 10 ng/mL and
0.1 mg/mL, respectively.
Immunohistochemistry
Immunohistochemistry (IHC) was performed as previously
described [46,47] with minor modifications. Briefly, 6 mm-thick
tissue sections or high density ovarian tissue core microarray slides
(OV1001 and OV2082, US Biomax, Rockville, MD) were
deparaffinized and rehydrated. Antigen retrieval was performed
by immersing tissues in target antigen retrieval buffer (TARH,
Dako, Carpinteria, CA) in a steamer (Black and Decker, Hunt
Valley, MD) for 15 minutes, followed by 15 minutes cooling on the
bench top. Primary antibody, mouse anti-human S100A6
antibody (Sigma-Aldrich, St. Louis, MO) at 1:700 dilution, and
biotinylated goat anti-mouse IgG secondary antibody (Dako,
Carpinteria, CA) were used. Reactions were developed using a
peroxidase-based streptavidin detection method (Vector Labs,
Burlingame, CA) and 3,39-diaminobenzidine tetrahydrochloride
(DAB) (Invitrogen, Carlsbad, CA) as chromogen substrate.
Negative reaction control included substitution of antibody diluent
for the respective primary antibodies on tissue sections and array
slides.
Serum S100A6 Quantification by ECLISA and Data
Analysis
Antigen-capture sandwich immunoassay employing electroche-
miluminescence technology (ECLISA) (Meso Scale Discovery
(MSD), Gaithersburg, MD) was developed to quantify serum
S100A6 levels. Two custom rabbit anti-human S100A6 polyclonal
antibodies were generated for this study. The capturing antibody,
C1, was generated against amino acids 42–90 of human S100A6
(Primm Biotech, Inc. Cambridge, MA), while a detecting
antibody, 9249B, was raised against a peptide corresponding to
amino acids 82–90 of human S100A6 (Rockland, Gilbertsville,
PA). Microtiter plates (MULTI-ARRAY, MSD, Gaithersburg,
MD) were coated with 4 mg/mL capturing antibody (C1) and
blocked with 1% casein. Test sera diluted in 0.16% SDS in
phosphate buffered saline (PBS, pH 7.4) were added to the coated
plates and incubated for 1 hour at room temperature. An MSD-
TAG labeled secondary anti-S100A6 antibody (9249B), prepared
according to manufacturer instructions (MSD, Gaithersburg,
MD), was used to detect captured S100A6. A 620 nm electrolu-
minescent signal was generated and detected using Sector Imager
2400 (MSD, Gaithersburg, MD).
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a standard curve to quantify serum S100A6 using the ECLISA.
Four-fold serial dilutions of recombinant S100A6 protein starting
from 20 mg/mL to 3.05610
24 mg/mL were included (in triplicate)
in each analysis performed. Additional assay control included
analysis of the same known positive and negative serum samples
with each run. ECLISA signals were plotted vs. the known
concentrations and fit with a four-parameter nonlinear logistic
regression model to obtain a standard curve of S100A6. The
standard curve run for each assay was then used to back-calculate
the S100A6 concentrations in serum samples, within that assay,
from the ECLISA signals. During preliminary development, the
four-parameter model was used to assess inter-run immunoassay
precision of five standard curves generated on different dates. The
five standard curves were found to be statistically equivalent with
respect to their lower asymptote, ‘slope’ and ‘50% maximal
response’ parameters.
Data in this study were analyzed using parametric and
nonparametric statistical methods, correlation and regression
techniques, and nonlinear hierarchical mixed-effects regression
models [48–53] using S-Plus, R, SAS and MSD (MSD,
Gaithersburg, MD) software [53–55]. Regression, inverse regres-
sion and calibration analyses were employed to determine whether
S100A6 serum concentrations could be used as a correlate for
tumor burden. Specifically, linear regression analysis was per-
formed on (log10) photon flux output (bioluminescent signal) vs.
(log10) numbers of inoculated cells to produce a standard
calibration curve with intercept and slope parameter estimates
2.27 and 1.01, respectively. An inverse prediction equation: log10
(cell number)=(log10 (photon flux output)22.27)/1.01 was
derived from the regression analysis to obtain estimates of
predicted cell numbers, along with their 95% confidence (fiducial)
limits, to predict tumor burden from the photon flux output of live
animals. Care was taken in the modeling process to satisfy
homogeneity and homoscedasticity requirements in the regres-
sion/calibration analyses. ECLISA signals from serial dilutions of
recombinant S100A6 protein were analyzed using the four-
parameter nonlinear regression model, y=b2 + ((b12b2 /(1 + (x/
b3 )ˆ
b4)), in which b1, b2, b3, and b4 represent, respectively, lower
and upper asymptotes, half-maximal concentration, and ‘slope’
factors [49]. Nonlinear regression model fits and back-calculations
of S100A6 serum concentrations were obtained from software
developed for this study using S-Plus and R [54,55]. For the
purpose of assigning S100A6 concentration values to 5 serum
specimens with ECLISA signal responses above the calibration
standard curve plateau, a working ECLISA signal value,0.01%
below the upper asymptote was entered into the back-calculation
computer routine to provide conservative estimates of serum
S100A6 levels for these cases. Qualitatively, the relative concen-
tration of these was verified by Western blot.
Comparisons of tumor vs. saline control treatment conditions
were carried out using parametric (t-tests, Welch’s modified t-tests
for unequal variances) and nonparametric (Wilcoxon Rank Sum)
statistical tests. Assumptions regarding homogeneity of variance
were routinely examined and appropriate tests applied. For
simplicity, probability values from the Wilcoxon Rank Sum test
are reported for comparisons of tumor vs. saline control treatment
conditions at days 9, 15 and 21, respectively for the mice in the 3
rd
cohort. All statistical tests were two-sided; probability values less
than 0.05 were considered significant.
Human Sera Study Set
The study set involved 66 serum specimens collected with
institutional approval at two Italian medical centres (Department
of Obstetrics and Gynaecology, University of Brescia, and Centro
di Riferimento Oncologico (CRO), Aviano). Samples were
obtained from fasting patients either the day prior to, or the day
of, surgical intervention, before induction of anaesthesia for
treatment. Participation of patients and the collection of samples
for the study were approved by the respective Institutional Review
Boards, and written informed consent was obtained from all
patients enrolled. Twenty-three (34.8%) specimens were classified
as early stage (I-IIb) (median patient age, 53 (range 24–68)), and 43
specimens (65.2%) were advanced stage (IIc-IV) OVCA (median
patient age, 60 (range 35–89)). Histologically, there were 20
serous, 5 endometrioid, 6 mucinous, 5 clear cell, and 13
undifferentiated OVCA. Two cases were classified as borderline
tumors (one serous, one mucinous). There was 1 germ cell OVCA
and 14 cancers were not otherwise specified. Blood samples were
collected in 7.5 mL S-Monovette vials (Sarstedt, Verona, Italy)
containing clot-activator and were maintained at room tempera-
ture for up to 30 to 90 minutes, after which all samples were
centrifuged at 4000 rpm for 20 minutes. Serum was stored at
280uC in aliquots of 500 microliters.
Immunoblotting of Reverse Phase Protein Microarray and
Data Analysis
Human serum S100A6 levels were determined by reverse phase
protein microarray (RPMA) technology. Serum handling, prepa-
ration, and analysis of arrays have been described previously [56],
including successful application of the technology to low
abundance analyte measurement in human sera [43,44]. Briefly,
sera (approximately 60 nL) had been arrayed in triplicate through
multiple depositions as 350 mm diameter spots onto Nitrocellulose
FAST slides (Whatman, Florham Park, NJ), in such a fashion to
obtain even interposition of cases and controls throughout the
slide, using a 2470 Arrayer (Aushon BioSystems, Burlington, MA).
Slides were stored at 220uC with a desiccant (W.A. Hammond
Co. Wenia, OH) until assayed. Controls included recombinant
human S100A6 protein (diluted 1:40 in extraction buffer) spiked
into normal mouse serum (S100A6-negative by WB and ECLISA),
and arrayed as calibration standards in a ten points dilution curve
(1:2) with starting concentration of 4.16 ng/mL. Three serum
samples from mice, two with OVCA xenografts and one normal
mouse, were included in the slide as additional positive and
negative controls. Appropriate results were previously obtained for
these control mouse samples using Western blot and ECLISA.
RPMA slides were blocked in I-Block (Applied Biosystems,
Foster City, CA) and incubated with C1 anti-S100A6 at 73 ng/
mL, followed by secondary antibody (BA-1000, Vector Labs,
Burlingame, CA) at 1:200,000 dilution. All washes were preformed
with Tris-buffered saline (0.05 M Tris-HCl, 0.15 M NaCl, pH 7.6)
with 0.1% Tween 20. Staining was performed by means of an
automated slide stainer (DAKO, Carpinteria, CA) and signal was
generated as previously described [56]. A negative slide probed
with secondary antibody only was prepared to determine the level
of background signal due to nonspecific binding of secondary
antibody. A Sypro Ruby (Molecular Probes, Eugene OR) staining
was carried out subsequently to determine the total protein
quantity for normalizing the scanned optical staining intensity
values of the primary antibody. Slides were scanned on a flatbed
optical scanner using greyscale mode and 16-bit images/600dpi.
ImageQuant analysis software (www.imsupport.com) was used to
determine spot intensities. All spot intensity values were subjected
to local background subtraction, secondary antibody alone
background subtraction, and normalization relative to total
protein intensities. These steps were taken to ensure that changes
in levels of protein expression were not simply due to differences in
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intensity values obtained were computed as means from the
normalized background-corrected triplicate values for each
sample. Early stage and advanced stage patients data were then
compared by means of a two-sample t-test after testing for
homogeneity of variance and normality.
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